CLINICAL TRIAL HIGHLIGHTS
CLINICAL TRIAL ID: NCT02831686
CLINICAL TRIAL ID: NCT02332850
Isatuximab, Kyprolis ® (carfilzomib) and Dex
versus Kyprolis-Dex
Eligible Patients: Eligible Patients:
Patients whose multiple myeloma has relapsed or is
resistant to at least one immunomodulatory drug and at
least one proteasome inhibitor. Patients with multiple myeloma previously treated with
two lines of treatment and who have measurable serum
M-protein and/or urine M-protein.
Key Information: Key Information:
This study is testing the safety of a combination of two
study drugs — Selinexor (a selective inhibitor of nuclear
export compound) and Ninlaro (a proteasome inhibitor)
— plus a low dose of dex. This study seeks to demonstrate that isatuximab, an anti-
CD38 inhibitor in the same class as Darzalex, ® combined
with Kyprolis and dex results in greater Progression Free
Survival (PFS) when compared to Kyprolis-dex alone.
Idasanutlin plus Ninlaro-Dex in Patients with Relapsed
Multiple Myeloma
Eligible Patients:
Patients with a 17p deletion who have myeloma
that has relapsed.
Key Information:
This Phase I/II trial studies the side effects and
best dose of idasanutlin (an inhibitor of MDM2) and
Ninlaro-dex in treating patients with multiple myeloma
that has relapsed. Idasanutlin may cause cancer cells
to self-destruct.
Selinexor (KPT-330), Ninlaro ® (ixazomib)
and Dexamethasone (dex)
CLINICAL TRIAL ID: NCT02633059
The Multiple Myeloma Research Consortium (MMRC), the MMRF clinical network of 25 centers in the United
States and Canada, evaluates novel agents and combinations for their safety, efficacy, and feasibility in Phase I
& II clinical trials. To date, the MMRC has conducted over 80 clinical trials, 26 of which are currently ongoing.
CLINICAL TRIAL ID: NCT02431208
Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1]
Antibody) Alone or in Combination with an
Immunomodulatory Drug and/or Darzalex (Daratumumab)
Eligible Patients:
Patients with relapsed multiple myeloma and those who
have undergone autologous stem cell transplantation.
Key Information:
This nationwide trial evaluating atezolizumab (atezo)
alone and in combinations: atezo and Darzalex; atezo,
Darzalex, and Revlimid ® (lenalidomide); and atezo,
Darzalex, and Pomalyst ® . Atezo is an antibody against
PD-L1 (programmed death-ligand 1) and helps T-cells
recognize cancer cells so that they can be killed.
Question about clinical trials? Please call our patient support center at 1.866.603.6628
To search for clinical trials, visit MyelomaTrials.org
a cce l e rat o r • Su m m e r 2 0 18
9